Transcript Catheter Ablation of Atrial Fibrillation in the Elderly

Catheter Ablation of Atrial
Fibrillation in the Elderly
Burr Hall, MD*
Wojciech Zareba, MD, PhD*
Scott McNitt, MS*
Darren Traub, DO**
James Daubert, MD***
*University of Rochester Medical Center: Rochester, NY
**St. Luke’s Hospital and Health Network: Bethlehem, PA
***Corresponding author. Duke University Health
System: Durham, NC
 Epidemiology





of atrial fibrillation (AF)
AF is the most common arrhythmia in clinical
practice
Approximately 2.2 million people in US have
paroxysmal or persistent AF
4.5 million in the European Union1,2
This may be an underestimate of the current
AF burden
Population demographics predict a substantial
growth of the AF population over the next 3040 yrs
1)
Arch Intern Med. 1995;155:469-473
2)
Fuster et al. J Am Coll Cardiol, 2006;
48:149-246
AF is a disease of the elderly

AF affects




0.4 – 1% of general population
8% of those >80 years old
The median age of an AF patient
is 75
70% of AF patients are ages 65
to 85
Go et al. JAMA 285: 2370-2375, 2001
Fuster et al. J Am Coll Cardiol, 2006; 48:149-246
Between 1960 and 1990, the US population aged 65 and older grew by 88%;
compared to 34% among those less than 65 years old.
>65 years old
Age and Projected Prevalence of AF
Atria Study
Go et al; JAMA; 2001
Projected Number of Persons with AF in the United
States Between 2000 and 2050
Miyasaka Y, et al. Circulation 2006;114:119-125.
Hospitalizations for Atrial
Fibrillation
•Hospitalizations with AF as 1° diagnosis ↑ 34% from 1996 to 2001
•In past 20 years admissions with AF listed in the diagnoses ↑66%
Wattigney et al. Circulation, 108 (6): 711, 2003
What is wrong with having AF?

Stroke risk

Four to six times the
general population

Associated with a
doubling of all cause
mortality

CHF exacerbation


Systolic heart failure
Diastolic heart Failure

Tachycardia-induced
cardiomyopathy

Economic burden


$3,600 year/patient
6.7 billion cost burden to
US
Adapted from Dorian et al. JACC 2000. 36;1303-09
ACC/AHA Guidelines for AF2006
What is wrong with having AF?

Symptoms

Often debilitating
100
90
80
70
60
50
40
30
20
10
0
AF
CHF
Post MI
Healthy
General
Health
Vitality
Social
Function
Adapted from Dorian et al. JACC 2000. 36;1303-09
ACC/AHA Guidelines for AF2006
25-40% of patients with paroxysmal atrial fibrillation
(PAF) will progress to chronic AF over a 10-year period
NORMAL
ATRIUM +
Trigger
(pulmonary veins,
preexisting
heterogeneity)
DISEASED
ATRIUM + Trigger
(?Accentuation of
preexisting
heterogeneity)
AF (short duration)
REMODELING
PERMANENT
Atrial Fibrillation
AF (variable
duration)
Shivkumar K and Weiss JN. Atrial fibrillation from cells to computers. Cardiovasc Res. 2001.
Wijffels MCEF. Circulation 1995
Management of Atrial Fibrillation
 1)
Rate control and anti-coagulation
 2)
Rhythm control with anti-arrhythmic
agents (AADs) and anti-coagulation
 3) AVJ
ablation and pacemaker placement
 4) Atrial
fibrillation ablation
AFFIRM
 Did AFFIRM
actually study rate control
versus rhythm control in an elderly
population?
 Was
there truly equivalence between the
two strategies?
The down side of rate control

Rate control with AV nodal blocking agents was not
satisfactory in 20% of patients

5.2% required AVJ ablation with pacemaker placement


Invasive strategy making patients 100% pacemaker dependent
14.9% (actuarial) crossover to AAD’s at 5 years
•In AFFIRM, all of the mortality benefit associated with the
maintenance of SR appears to have been counterbalanced by
the increased mortality risk associated with AAD drug use
•This raises the question “What if there was a safer method to
maintain SR in this population?”
AFFIRM : Antiarrhythmic Drug Sub-study
(n=106)
(P<0.01)
(n=125)
(n=116)
J Am Coll Cardiol. 2003;42:20-29.
Pharmacologic Approaches to
Maintain Sinus Rhythm
 Low

success rate
1-year AF recurrence of approximately
50%
• Regardless of anti-arrhythmic agent
• Amiodarone best agent ~ 65% SR at 16 months

Side effects common
• Amiodarone


Attrition rate of therapy due to many side effects
• 18% at 16 months in CTAF trial
• 11% at one year AFFIRM trial
Risk of pro-arrhythmia
Am J Cardiol 1991;68:335-41
NEJM 2000;342:913-20
Am J Geriatr Cardiol, 2002; 11: 370–375
Heart Rhythm, 2007; 4: 1577–1599.
The Elderly patient and AAD’s
 Age
related senescence alters the
pharmacokinetics of AADs



metabolism less predictable
increased predilection for side effects
Increased risk of pro-arrhythmias
Dayer MB, Hardman SMC. Special problems with antiarrhythmic drugs in the elderly: Safety,
tolerability, and efficacy. Am JGeriatr Cardiol, 2002; 11: 370–375.
Curtis AB, Rich MW. Atrial fibrillation in the elderly: Mechanisms and management. Heart Rhythm,
2007; 4: 1577–1599.
Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. AmJ Med, 2007; 120: 481–487.
Meta-analysis of 1100 patients after AV junctional ablation and pacemaker placement for
medically refractory atrial fibrillation, atrial flutter or atrial tachycardia: left ventricular
function, healthcare use, and New York Heart Association (NYHA) functional classification
Copyright ©2000 American Heart Association
Wood, M. A. et al. Circulation 2000;101:1138-1144
Catheter Ablation of the AV
Junction

Advantages





Improved rate control
Improved QOL
Improved LVEF
No AADs
Less hospitalizations

Disadvantages




Pacemaker
dependence
Procedure
complications
Continued embolic risk
Progression of AF to
more permanent
What about AF ablation?
94% in PV’s
Diagram of the Sites of 69 Foci Triggering Atrial Fibrillation in 45 Patients
Haissaguerre M et al. N Engl J Med 1998;339:659-666
Important Insights into Pulmonary Vein
Architecture
Ho, S Y et al. Heart 2001;86:265-270
Copyright ©2001 BMJ Publishing Group Ltd.
Muscular Sleeves with Gaps of Fatty Tissue and
Fibrosis
Ho, S Y et al. Heart 2001;86:265-270
Copyright ©2001 BMJ Publishing Group Ltd.
Mechanisms of AF
Triggers: Rapid
discharges from focal
sources
PV
Extra PV sites
Rotors: perpetuate AF
(in PV-LA junction)
Atrial structural
remodeling; less
organized conduction
resulting in fibrillation
Vagal inputs
PVI vs
AAD as
1st line
therapy
for PAF
•Significant
reduction in AF
recurrence at 1year with PVI
• QOL also
significantly
improved with PVI
compared to AAD’s
Age > 70
exclusion
criteria
There is a disconnect between
the AF ablation population and
the real AF population!!!
P
O
. J Cardiovasc Electrophysiol, 2007; 18: 23–38
AF ablation in the Elderly Review of
the Literature
 There
are no prospective randomized
controlled trials comparing the safety and
efficacy of catheter ablation for
paroxysmal or persistent AF in the elderly
to best medical therapy or alternative
strategies such as AV node ablation plus
pacemaker placement
J Cardiovasc Electrophysiology 2005; 16: 457-61
Pappone HRS 2009
Can we use the same AF ablation
strategies in younger and older
patients?
Older dogs in sinus rhythm (white
circles) had lower Vmax and
longer AP duration compared to
adult dogs (black circles)
Older dogs in SR had significantly greater
heterogeneity of repolarization than adult
dogs (SD APD90 = standard deviation of
action potential duration to 90%
repolarization) as well as a larger interregional
dispersion of AP duration. These spatial
differences in AP duration and refractoriness
likely facilitate re-entry; initiation and
perpetuation of AF.
Conclusion

Catheter ablation of AF can be safely performed in an
elderly population.


There may be a slightly increased risk of peri-procedural
complications
Catheter ablation appears to be efficacious in an elderly
population


All data based on retrospective analyses
More elderly remain on AADs post-ablation
• This may be an acceptable endpoint for an elderly patient with
symptomatic AF

The next step is to perform large scale, randomized trials
like AFFIRM to more definitively establish the role of
catheter ablation in treating elderly patients with atrial
fibrillation